Technical Analysis for OVID - Ovid Therapeutics Inc.

Grade Last Price % Change Price Change
C 3.97 -1.24% -0.05
OVID closed down 1.24 percent on Friday, March 5, 2021, on 1.47 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical OVID trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
180 Bullish Setup Bullish Swing Setup -1.24%
Calm After Storm Range Contraction -1.24%
Wide Bands Range Expansion -1.24%
Gilligan's Island Sell Setup Bearish Swing Setup -1.73%
Crossed Above 20 DMA Bullish -1.73%
MACD Bullish Signal Line Cross Bullish -1.73%
New Uptrend Bullish -1.73%
Expansion Breakout Bullish Swing Setup -1.73%
Older End-of-Day Signals for OVID ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ovid Therapeutics Inc. Description

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Disorders Symptoms Neurological Disorders Epilepsy Syndromes Takeda Pharmaceutical Company Urological Disorders Genodermatoses Sedatives Fragile X Syndrome Anticonvulsants Rare Neurological Disorders

Is OVID a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.4
52 Week Low 1.8
Average Volume 4,710,174
200-Day Moving Average 5.16
50-Day Moving Average 2.92
20-Day Moving Average 3.40
10-Day Moving Average 3.31
Average True Range 0.40
ADX 30.08
+DI 36.51
-DI 19.38
Chandelier Exit (Long, 3 ATRs ) 3.56
Chandelier Exit (Short, 3 ATRs ) 3.77
Upper Bollinger Band 4.12
Lower Bollinger Band 2.68
Percent B (%b) 0.9
BandWidth 42.16
MACD Line 0.17
MACD Signal Line 0.10
MACD Histogram 0.0686
Fundamentals Value
Market Cap 251.43 Million
Num Shares 63.3 Million
EPS -1.78
Price-to-Earnings (P/E) Ratio -2.23
Price-to-Sales 52.66
Price-to-Book 6.63
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.66
Resistance 3 (R3) 4.60 4.30 4.55
Resistance 2 (R2) 4.30 4.13 4.34 4.51
Resistance 1 (R1) 4.14 4.02 3.99 4.20 4.47
Pivot Point 3.84 3.84 3.77 3.88 3.84
Support 1 (S1) 3.68 3.67 3.53 3.74 3.47
Support 2 (S2) 3.38 3.56 3.42 3.43
Support 3 (S3) 3.22 3.38 3.40
Support 4 (S4) 3.28